Printer Friendly

Company expands patent portfolio.

NEWARK, Calif., March 20, 2013 -- Stem-Cells, Inc. (NASDAQ: STEM) has acquired from NsGene A/S, a privately held Danish biotechnology company, a patent family claiming GFAP+ Nestin+ cells, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148.

GFAP and Nestin are proteins that are co-expressed by certain key cells found in the human central nervous system. Each patent claims a cell culture of undifferentiated GFAP+ Nestin+ cells wherein one or more cells have the capacity to differentiate into neurons and glia as do many neural stem and progenitor cells described by researchers. The invention claimed by the patents resulted from research conducted at NsGcnc while in pursuit of cell-based treatments for Parkinson's disease. The terms of the patents extend into 2020 and 2021.

Contact: http://www.stemcellsinc.com

COPYRIGHT 2013 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Patents
Publication:Stem Cell Business News
Date:Mar 25, 2013
Words:136
Previous Article:Doctors file in court to defend patents for genetic research.
Next Article:Company awarded patent for processing umbilical cord blood for therapeutic use.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters